|Abstract:||Epithelioid sarcomas are rare, mesenchymal tumors of unknown histogenesis and display multidirectional differentiation, which is predominantly epithelial. They have no normal cellular counterpart and differ from both synovial sarcoma and carcinoma. They account for less than 1% of all soft tissue sarcomas and are usually slow growing, with peak incidence in young adult men and occur predominantly in extremities. Histologically, they form nodules, with central necrosis surrounded by bland, polygonal cells with eosinophilic cytoplasm and peripheral spindling. They regularly express vimentin, cytokeratins, epithelial membrane antigen, and CD34, whereas staining is usually negative with S100, desmin, and FLI-1. Ultrastructurally, they display epithelial and mesenchymal features, including myofibroblasts differentiation. They manifest no specific cytogenetic findings, but several cases have displayed chromosomal abnormalities in 22q region. Clinically, they have a high recurrence rate, and up to 50% of epithelioid sarcomas metastasize. Proximal, fibroma-like, and angiomatoid variants have been described. The proximal variant (with larger cells, prominent nucleoli, and rhabdoid changes) is clinically more aggressive.|
|Article Type:||Clinical report|
Epithelial tumors (Diagnosis)
Armah, Henry B.
Parwani, Anil V.
|Publication:||Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165|
|Issue:||Date: May, 2009 Source Volume: 133 Source Issue: 5|
|Topic:||Canadian Subject Form: Epithelial tumours|
Epithelioid sarcoma (ES) is a soft-tissue tumor, composed of large,
polygonal cells resembling carcinomas. Epithelioid sarcoma was first
characterized as a distinct clinicopathologic entity by Enzinger in 1970
(1) after being described as aponeurotic sarcoma in 1961 by Laskowski
(2) and as large-cell sarcoma of the tendon shealth in 1968 by Bliss and
Reed. (3) It is a relatively rare, soft-tissue sarcoma (accounting for
<1% of all soft-tissue sarcomas) of unknown histogenesis, usually
slow-growing throughout a period of years, with a seemingly benign
pathomorphologic appearance and is, therefore, often misdiagnosed on
first encounter. (4) Epithelioid sarcoma is a mesenchymal tumor with a
predominant epithelial differentiation, showing reactivity for both
epithelial and mesenchymal markers, such as cytokeratin, epithelial
membrane antigen, vimentin and CD34. (4-7) Unlike most soft tissue
sarcomas, ES characteristically spreads via lymphatics to noncontiguous
areas of skin, deep soft tissue, fascia, and bone, as well as by direct
In its conventional or classic form, it is usually a solitary or multifocal tumor involving the dermis, subcutis, or deeper soft tissues in the distal extremities of young adults in 55% to 60% of cases (4,6) and is frequently associated with ulceration of the overlying skin. The classic-type ES is rare in children and older individuals, and occurs more commonly in men than in women. Epithelioid sarcoma has a tendency to develop local recurrences and metastasis thereafter to regional lymph nodes, lung, bone, brain, and other locations, including the scalp, which has been noted in 40% to 50% of cases and can be reduced by adequate surgery. (4-6) The recognized adverse prognostic factors include male sex, older age, large size, multifocality, proximal or axial location, depth of invasion, mitotic activity, necrosis, vascular invasion, tumor hemorrhage, nodal involvement, rhabdoid cytomorphology, and inadequate excision. (4-6,10)
Microscopically, ES is usually multinodular with a central necrosis surrounded by bland polygonal cells with eosinophilic cytoplasm and peripheral spindling. The classic-type ES has cells with only mild atypia, although they can appear more pleomorphic in recurrences or metastases. Therefore, it has a wide differential diagnosis from numerous benign and malignant conditions, including granuloma annulare, melanoma, and epithelioid vascular neoplasms. (4-6) Hence, ES is characterized by diagnostic difficulties, both clinically and histopathologically, which result in a high frequency of initial misdiagnosis and the loss of crucial treatment time.
Apart from the more common, classic-type of ES (granuloma-like), angiomatoid or angiosarcoma-like and fibrous histiocytoma-like or fibroma-like subtypes were first noted in 1991 and 1992, respectively. (11,12) Lately, an aggressive subtype of ES has been identified, known as the proximal type or axial type. (13) The proximal subtype was first described as a distinct subtype of ES in 1997. (13) Histologically, the proximal subtype differs from the classic type by its larger epithelioid cells, with vesicular nuclei, and prominent nucleoli; copious, eccentric cytoplasm; marked cytologic atypia; and frequent rhabdoid features. (13) Tumoral necrosis is also a common finding in the proximal subtype, but it is usually without the granuloma-like appearance of the classic type. (13,14) Clinically, the proximal subtype differs from the classic type by its multinodular growth pattern, more frequent occurrence in older patients, more proximal/axial distribution (mainly, but not exclusively, involving the pelvic, perineal, and genital areas), more deep-seated location, and more aggressive clinical behavior from the outset (with more frequent recurrence, earlier development of metastasis, and a higher incidence of tumor-related deaths). (13,14) However, it is not yet certain whether the reduced survival associated with the proximal subtype is due to its different histomorphology or to its lesser surgical resectability because of its deeper location, more proximal distribution, and/or larger size at diagnosis.
Grossly, ES is a predominantly solid, multinodular mass, with an ill-defined, diffusely infiltrative, glistening, gray-tan appearance and multiple areas of hemorrhage and necrosis. (4-6,8)
Histologically, ES is characterized by irregular nodules composed of a proliferation of relatively uniform, polygonal or epithelioid cells (Figure 1), often with loss of cohesion, which merge peripherally into spindle cells embedded in desmoplastic fibrous stroma without a clear demarcation. The cells usually have relatively abundant, deeply eosinophilic cytoplasm and minimal pleomorphic nuclei (Figure 1, inset) with occasional mitoses (often less than 5 per 10 high-power fields). The tumor is often associated with lymphocytic infiltration, mucin deposition, hemorrhage, hemosiderin deposition, and vascular invasion. Ulceration and necrosis are typical, with the frequent central necrosis (Figure 2), resulting in a pseudogranulomatous appearance, which can mimic benign necrobiotic granulomatous lesions. Stromal changes include desmoplasia, focal calcification, or metaplastic ossification, and rarely, myxoid change. (4-6,8)
Less commonly, ES can exhibit a prominent cord of bland spindle cells with a collagen-rich storiform pattern (the fibroma-like variant (7,12) with an affinity for bone involvement), a vascular proliferation with red blood cells in the tumor area (the angiomatoid or angiosarcoma-like variant (7,17); Figure 3), or a solid growth pattern with larger cells with vesicular pleomorphic nuclei, prominent nucleoli, and focal or prominent rhabdoid features (proximal type or rhabdomyosarcoma-like variant (13,14); Figure 4). These rhabdoid features include intracytoplasmic, paranuclear, spheroid, hyaline-like globules compressing and displacing the nucleus eccentrically (Figure 4, inset). Additionally, the proximal variant is characterized by marked cytologic atypia, frequent mitosis, vascular invasion, and absence of a granulomatous appearance. (13,14) Rarely, a tumor has features of both the classic and proximal variants. (18) Although the concept of proximal-type ES is not yet universally accepted, Sur and Nayler18 described the hybrid form, showing transitions from the morphologically classic-type ES to the high-grade morphology typical of proximal-type ES and suggested that proximal-type ES is a distinct entity.
Although there are several reported immunohistochemical studies on ES, a specific tumor marker for the diagnosis of this tumor has not yet been established. Virtually all cases of ES are positive for cytokeratins (Figure 5) and epithelial membrane antigen (Figure 6). (4-7) Among the cytokeratins, the reported percentage of expression in ES is as follows: CK8, 94%;CK14, 48%;and CK19, 72%, but rarely, CK7, 22%;CK20, 15%;or CK5/6, 30%, focal. (7) Most cases co-express vimentin (Figure 7) and cytokeratin, but a few are vimentin-negative. (19) CD34 staining is positive in more than half of ESs. (4-7) The other endothelial markers, CD31 (20) and FLI-1 (21), are usually negative. Smooth muscle actin and neurofilament are often positive, especially in the spindle cells. (4-7) Desmin was positive in several cases in one study, (13) but negative in all variants of ES examined in a larger series. (7) Most cases are negative for S100, although HMB-45 was found in a minority of cells in 3 cases of proximal-type ES. (13)
However, no single marker was able to distinguish the 4 main histologic subtypes of ES.4-7 More recent studies (22-24) have suggested that CA 125 (Figure 8) immunoreactivity, with an elevated serum CA 125 level, could be a useful tumor marker for diagnosing ES and monitoring its clinical course. Ten (91%) of 11 ESs (comprising 10 classic types and 1 proximal type) were positive for CA 125, but other soft-tissue tumors, including 6 synovial sarcomas, 6 clear cell sarcomas, 8 leiomyosarcomas, 6 rhabdomyosarcomas, 14 liposarcomas, 5 malignant peripheral nerve sheath tumors, 10 malignant fibrous histiocytomas, 17 desmoid tumors, 6 squamous cell carcinomas (cutaneous squamous cell carcinoma of the distal extremities), 2 rheumatoid nodules, and 7 foreign body granulomas used as controls were negative for CA 125. (23)
Electron Microscopic Features
Ultrastructurally, ES displays a spectrum of appearances from undifferentiated cells, and carcinoma-like epithelial differentiation to mesenchymal features, including myofibroblastic differentiation. (5,13,25,26) These features include desmosome-like intercellular junctions, surface microprocesses or filopodia, and interdigitating cell membranes indicating epithelial differentiation. (5,25,26) Other features are dilated, rough endoplasmic reticulum; intermediate filaments; and peripheral myofilament bundles, especially in the spindle cells at the periphery of the nodules, indicating fibrohistiocytic, fibroblastic, or myofibroblastic differentiation. (5,25,26) The rhabdoid cells in the proximal subtype show abundant paranuclear, cytoplasmic, well-delineated aggregates of intermediate filaments, indenting the nucleus eccentrically. (13)
[FIGURES 1-4 OMITTED]
Cytogenetic and Molecular Features
There are no consistent or specific cytogenetic findings in ES, but several cases display chromosomal abnormalities in the 22q region. (27,28) Additionally, inactivation of a tumor-suppressor gene SMARCB1/INI1, located at band 22q11, has been found in proximal, but not classic type, ES. (29)
Epithelioid sarcoma has many histopathologic mimics, including benign and malignant conditions, such as granuloma annulare, necrobiosis lipoidica, chronic granulomatous inflammation (especially rheumatoid nodules), fibrous histocytoma, nodular fasciitis, fibromatosis, giant cell tumor of tendon sheath, melanoma, clear-cell sarcoma of the tendon and aponeurosis (amelanotic melanoma of soft part), schwannoma, metastatic squamous cell carcinoma, metastatic adenocarcinoma (especially renal cell carcinoma), synovial sarcoma, epithelioid hemangioendothelioma, epithelioid leiomyosarcoma, and malignant extrarenal rhabdoid tumors of the soft tissue. (1,4-8,13,14,18,22-24,30)
The bland cytology and pseudogranulomatous appearance of classic-type ES in the dermis can lead to misinterpretation as granuloma annulare, chronic granulomatous inflammation (especially rheumatoid nodules), or other necrotizing granuloma (especially necrobiosis lipoidica). (1,4-8) However, the presence of mitotic activity should raise the index of suspicion for ES, and the presence of diffuse epithelial marker positivity indicates the correct diagnosis.
Epithelioid sarcomas are sometimes composed of spindle-shaped cells, and they may be confused with other malignant spindle-cell neoplasms, such as synovial sarcomas, fibrosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignant extrarenal rhabdoid tumor, epithelioid hemangioendothelioma, and amelanotic melanoma. However, ESs are the only one of these to possess the combination of cytokeratin and vimentin positivity and a pseudogranulomatous pattern. (1,4-8)
[FIGURES 5-8 OMITTED]
Proximal-type ES should also be distinguished from other neoplasms with epithelioid and/or rhabdoid features, such as malignant extrarenal rhabdoid tumor, epithelioid rhabdomyosarcoma, melanoma, malignant peripheral nerve sheath tumor, and undifferentiated carcinoma. (13,14,22)
Appropriate immunohistochemical studies showing positivity for vimentin, cytokeratins, CD34, epithelial membrane antigen, and CA 125, and negativity for the S100 protein, HMB-45, FLI-1, and desmin, are helpful to exclude most of these other mentioned tumors from the differential diagnosis. Coexpression of vimentin and keratin is thought to be characteristic of ES. (1,4-8,13,14,18,22-24,30)
Carcinomas, both primary (especially those of adnexal origin) and metastatic, can have a presentation similar to ES. Carcinomas are nearly always CD34 negative, and although CD34 is only expressed in about 50% to 60% of ESs, this marker is particularly useful for diagnosing the deep-seated, proximal-type ES, which can be misdiagnosed as metastatic carcinoma of an unknown primary site. (4,7) Additionally, metastatic renal cell carcinoma may be delineated by virtue of its glandular and papillary pattern, despite the similarity in cell morphology.
Synovial sarcomas may have cytokeratin and vimentin positivity; however, the tumor cells are usually less pleomorphic, are oval to spindled, and often show areas of glandular differentiation, unlike ES. Synovial sarcoma can have plump epithelioid and even rhabdoid cells on occasion. The immunoprofile of the synovial sarcoma and ES can overlap, but synovial sarcoma is often positive for S100 protein and only very rarely CD34 positive. Finally, the specific t(X;18) of synovial sarcoma is not found in ES. (4,7)
Epithelioid angiosarcomas and hemangioendotheliomas may be cytokeratin positive, but they have areas suggestive of vascular channel formation or intracytoplasmic lumen, and they are usually positive for endothelial markers, such as CD34, CD31, or factor VIII, whereas ES is rarely positive for CD34, but it is negative for these latter markers. (4,7) Epithelioid vascular tumors can resemble ES, and additionally, some express CK. However, they differ from ES in being positive for CD31, factor VIIIa, and FLI 1 but negative for CD34. (4,7)
Rhabdomyosarcoma is readily excluded by immunohistochemistry, showing positive epithelial markers and an absence of desmin, myogenin, MyoD1. (4,7) It might not be possible to distinguish S100 protein-negative rhabdoid melanoma from proximal-type ES, especially as some of the latter have been reported to be HMB-45 positive. (5,13) Many tumors formerly diagnosed as malignant rhabdoid tumor are now classified as proximal-type ES. FanburgSmith et al (30) reported that all extrarenal rhabdoid tumors are negative for CD34 and have distinctive findings at chromosome 22, findings that are not observed in ES. Therefore, ES and extrarenal rhabdoid tumor are considered separate entities.
Epithelioid sarcoma is a tumor of uncertain differentiation and is described as being of unknown lineage. (4-7) However, the reported histomorphology, immunophenotype, and ultrastructure of ES suggest a mesenchymal neoplasm with multidirectional differentiation, including epithelial, histiocytic, fibroblastic, myofibroblastic, endothelial, and perineural. (4-7) Epithelioid sarcoma has no normal cellular counterpart and differs from both synovial sarcoma and carcinoma. (4) Notwithstanding its epithelial differentiation, ES differs from synovial sarcoma and carcinoma in many respects. It has been suggested that ES might represent a carcinoma of soft parts, but the absence of an in situ carcinoma component and the absence of a primary site of carcinoma elsewhere in the reported cases of ES, in addition to the immunophenotype of ES, especially the CK profile and the expression of CD34, differ from those of carcinomas, making this suggestion untenable. (4-7) Clinically, ES is often dermal and usually located in the extremities, features that would be exceptional for synovial sarcoma. Unlike synovial sarcoma, ES is not truly biphasic, but the spindle cells emerge at the edge of the tumor nodules with continuous transition from the polygonal cells and have no glandular formation, morphologically or ultrastructurally, and no external lamina. Additionally, synovial sarcomas display epithelial markers more focally, express CK7, which is infrequent in ES, and are almost always CD34-negative. (4-7) Cytogenetically, the t(X;18) with SYT-SSX fusion genes, which is characteristic of synovial sarcoma, is never found in ES, which has variable abnormalities, including, most commonly, those of the 22q region. (27,28)
CURRENT TREATMENT AND PROGNOSIS
Epithelioid sarcoma is an aggressive neoplasm, and local recurrence is the rule. It recurs persistently, often with successive lesions appearing more proximally, and eventually metastasizes. (4-6,10) Wide, total surgical excision with clear margins (amputation or wide en bloc excision) and high-dose chemoradiotherapy represent optimum treatment and achieve low rates of local recurrence. However, even this regimen is associated with a recurrence rate of between 34% and 77% (depending on the adequacy of initial excision), metastases in about 40% of the patients (primarily involving the lungs, regional nodes, scalp, bone, and brain), and a median overall survival of about 88 months for patients without distant metastases and just 8 months for those with distant metastases. (4-6,10) In the largest series of 202 cases of ES with follow-up, 77% recurred, and 45% metastasized predominantly to lungs (51%), local lymph nodes (34%), scalp and other skin areas (22%), bone, brain, liver, and pleura. (4) Metastases developed in 36% of patients without local recurrence. Adverse prognostic factors included proximal location (71% metastasized vs 38% of distal cases), amount of necrosis and vascular invasion, and inadequate excision. (4) Proximal-type ES is even more aggressive. In the series of Guillou et al, (13) 6 (43%) of 14 patients, with up to 8 years follow-up, developed metastases, and 5 patients (36%) died of the tumor. However, 6 patients (43%) were alive and well at last follow-up, including 1 patient (7%) with local recurrence at 2 months, who was disease-free at 8 years. (13) In a second series of 20 cases of proximal-type ES, 65% (13/20) developed local recurrence, and 75% (15/20) developed metastases, with 65% (13/20) dead of the disease. (14)
Unlike most soft-tissue sarcomas, metastases affecting the lymph nodes are common in ES. (4-6,8-10) However, the lungs are the most common site of distant metastases in ES. A prognostically ominous sign is lymph node involvement, although sex and tumor size are the most important determinants of outcome. (4-6,8-10) Women have a better prognosis, with up to 80% 5-year survival rate, whereas the survival rate for men at 5 years is 40%. (4-6,8-10) Favorable factors are young age at first diagnosis, female sex (78% survival rate vs 64% for men), (4) and small size of tumor (less than 5 cm). (4,8) Additionally, older age, multifocal local disease, initial proximal limb or axial location, depth of invasion, high mitotic activity, necrosis, vascular invasion, tumor hemorrhage, rhabdoid cytomorphology, and inadequate excision predict a poor survival free from distant metastasis. (4-6,10) Spillane et al8 found a 5-year survival of 70% and a 10-year survival of 42%, in a series with a metastatic rate of 40%. Because of the relatively indolent behavior, the incidence of late recurrence, and the continuing death rate, long-term follow-up is indicated in ES. (4)
Almost 40 years after Enzinger's first characterization of ES as a distinct clinicopathologic entity, ES is still of uncertain histogenesis (without a normal counterpart cell and a characteristic cytogenetic finding). However, it remains a distinct clinicopathologic entity with characteristic histomorphology, immunophenotype, and ultrastructure. The correct diagnosis of ES is essential because it can easily be misdiagnosed as another benign and less-aggressive malignant epithelioid lesions. Generally, the presence of large polygonal cells with prominent nucleoli and abundant necrosis on histology warrants the consideration of ES in the differential diagnosis. However, an immunohistochemical confirmation is a must for definitive diagnosis.
Accepted for publication July 10, 2008.
(1.) Enzinger FM. Epithelioid sarcoma: a sarcoma simulating a granuloma or a carcinoma. Cancer. 1970;26:1029-1040.
(2.) LaskowskiJ. Sarcoma aponeuroticum. Nowotory. 1961;11:61-67.
(3.) Bliss BO, Reed RJ. Large cell sarcomas of tendon shealth. Am J Clin Pathol. 1968;49:776-781.
(4.) Chase DR, Enzinger FM. Epithelioid sarcoma: diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985;9:241-263.
(5.) Fisher C. Epithelioid sarcoma of Enzinger. Adv Anat Pathol. 2006;13:114 121.
(6.) Evans HL, Baer SC. Epithelioid sarcoma: a clinicopathologicand prognostic study of 26 cases. Semin Diagn Pathol. 1993;10:286-291.
(7.) Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol. 1999;30: 934-942.
(8.) Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000;7:218 225.
(9.) Prat J, Woodruff JM, Marcove RC. Epithelioid sarcoma: an analysis of 22 cases indicating the prognostic significance of vascular invasion and regional lymph node metastasis. Cancer. 1978;41:1472-1487.
(10.) Baratti D, Pennacchioli E, Casali PG, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007;14:3542-3551.
(11.) von Hochstetter AR, Meyer VE, Grant JW, Honegger HP, Schreiber A. Epithelioid sarcoma mimicking angiosarcoma: the value of immunohistochemistry in the differential diagnosis. Virchows Arch A Pathol Anat Histopathol. 1991;418: 271-278.
(12.) Mirra JM, Kessler S, Bhuta S, Eckardt J. The fibroma-like variant of epithelioid sarcoma: a fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors. Cancer. 1992;69:1382-1395.
(13.) Guillou L, Wadden C, Coindre JM, KrauszT, Fletcher CD. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features: clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997;21:130-146.
(14.) Hasegawa T, Matsuno Y, Shimoda T, Umeda T, Yokoyama R, Hirohashi S. Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases. Mod Pathol. 2001;14:655-663.
(15.) Bloustein PA, Silverberg SG, Waddell WR. Epithelioid sarcoma: casereport with ultrastructural review, histogenetic discussion, and chemotherapeutic data. Cancer. 1976;38:2390-2400.
(16.) Puissegur-Lupo ML, Perret WJ, Millikan LE. Epithelioid sarcoma. Report of a case. Arch Dermatol. 1985;121:394-395.
(17.) von Hochstetter AR, Grant JW, Meyer VE, Honegger HP, Schreiber A. An giomatoid variant of epithelioid sarcoma: the value of immunohistochemistry in the differential diagnosis. Chir Organi Mov. 1990;75:158-162.
(18.) Sur M, Nayler SJ. Proximal epithelioid sarcoma--a misnomer. Histopathology. 2001;39:641-643.
(19.) Arber DA, Kandalaft PL, Mehta P, Battifora H. Vimentin-negative epithelioid sarcoma: the value of an immunohistochemical panel that includes CD34. Am J Surg Pathol. 1993;17:302-307.
(20.) Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Wil lebrand factor. Mod Pathol. 1994;7:82-90.
(21.) Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25:1061-1066.
(22.) Lee HI, Kang KH, Cho YM, Lee OJ, Ro JY. Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. Arch Pathol Lab Med. 2006;130:871-874.
(23.) Kato H, Hatori M, Kokubun S, et al. CA125 expression in epithelioid sarcoma. Jpn J Clin Oncol. 2004;34:149-154.
(24.) Kato H, Hatori M, Watanabe M, Kokubun S. Epithelioid sarcomas with elevated serum CA125: report of two cases. Jpn J Clin Oncol.2003;33:141-144.
(25.) Fisher C. Epithelioid sarcoma: the spectrum of ultrastructural differentiation in seven immunohistochemically defined cases. Hum Pathol. 1988;19:265-275.
(26.) Fisher C. The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology. 1990; 16:441-454.
(27.) Quezado MM, Middleton LP, Bryant B, Lane K, Weiss SW, Merino MJ. Allelic loss on chromosome 22q in epithelioid sarcomas. Hum Pathol. 1998;29: 604-608.
(28.) Lee MW, Jee KJ, Han SS, et al. Comparative genomic hybridization in epithelioid sarcoma. Br J Dermatol. 2004;151:1054-1059.
(29.) Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005;65: 4012-4019.
(30.) Fanburg-Smith JC, Hengge M, Hengge UR, Smith JS Jr, Miettinen M. Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol. 1998;2:351-362.
Henry B. Armah, MD; Anil V. Parwani, MD, PhD
From the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pa.
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Henry B. Armah, MD, Department of Pathology, University of Pittsburgh Medical Center, 200 Lothrop St, A610, Pittsburgh, PA 15213 (e-mail: firstname.lastname@example.org).
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|